FDA Updates Abacavir and Lamivudine Labeling
"On March 23, 2015, FDA approved revisions to the Epivir (lamivudine) and Ziagen (abacavir sulfate) labels to each provide for once-daily dosing in pediatric patients 3 months of age and older in combination with other antiretroviral agents for the treatment of HIV-1 infection."
The updated labeling for both drugs will be available soon at the FDA website.
More information is available:
FDA: Press release
AIDSinfo: Patient fact sheet on abacavir
AIDSinfo: Patient fact sheet on lamivudine
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - Category: Infectious Diseases Source Type: news
More News: Abacavir Sulfate | Abacavir Sulfate and Lamivudine | Department of Health | Health | HIV AIDS | Infectious Diseases | Pediatrics | Websites